Elevated heparanase expression is associated with poor prognosis in breast cancer: a study based on systematic review and TCGA data

Xu Sun; Ganlin Zhang; Jiayun Nian; Mingwei Yu; Shijian Chen; Yi Zhang; Guowang Yang; Lin Yang; Peiyu Cheng; Chen Yan; Yunfei Ma; Hui Meng; Xiaomin Wang; Jin-Ping Li

doi:10.18632/oncotarget.16575

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Elevated heparanase expression is associated with poor prognosis in breast cancer: a study based on systematic review and TCGA data

Xu Sun, Ganlin Zhang, Jiayun Nian, Mingwei Yu, Shijian Chen, Yi Zhang, Guowang Yang, Lin Yang, Peiyu Cheng, Chen Yan, Yunfei Ma, Hui Meng, Xiaomin Wang _ and Jin-Ping Li

PDF | HTML | How to cite

Oncotarget. 2017; 8:43521-43535. https://doi.org/10.18632/oncotarget.16575

Metrics: PDF 2664 views | HTML 4377 views | ?

Abstract

Xu Sun1, Ganlin Zhang1, Jiayun Nian1,2, Mingwei Yu1, Shijian Chen3, Yi Zhang1, Guowang Yang1, Lin Yang1, Peiyu Cheng1, Chen Yan1,2, Yunfei Ma1, Hui Meng1,2, Xiaomin Wang1 and Jin-Ping Li1,4

1 Department of Oncology, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing, China

2 School of Graduates, Beijing University of Chinese Medicine, Beijing, China

3 Department of Neurology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, China

4 Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden

Correspondence to:

Xiaomin Wang, email:

Keywords: heparanase, breast cancer, prognosis

Received: September 09, 2016 Accepted: March 10, 2017 Published: March 25, 2017

Abstract

Heparanase promotes tumorigenesis, angiogenesis, and metastasis. Here, we conducted a study based on systematic review and the Cancer Genome Atlas (TCGA) data that examined heparanase expression in clinical samples to determine its prognostic value. According to the meta-analysis and TCGA data, we found that heparanase expression was up-regulated in most breast cancer specimens, and elevated heparanase expression was associated with increased lymph node metastasis, larger tumor size, higher histological grade, and poor survival. These results suggest that targeting heparanase might improve treatments for breast cancer patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16575

Publication Alerts

Reviews:

Elevated heparanase expression is associated with poor prognosis in breast cancer: a study based on systematic review and TCGA data

Abstract